Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

Despite meaningful progress in HIV prevention, the HIV epidemic is far from over, with 31,000 new diagnoses in the U.S. each ...

The use of synthetic cathinones and other novel chemsex drugs is signaling the need to make long-acting injectable PrEP more accessible.

Tuberculosis (TB) remains the world's leading cause of death from a single infectious agent. A new study recently published ...

Lenacapavir, a groundbreaking HIV treatment, is set to transform South Africa’s approach to HIV prevention amidst funding ...

One in 10 clinics in SA — across 22 health districts in six provinces — could start to hand out a twice-a-year anti-HIV jab ...

The U.S. Preventive Services Task Force has been accused of being infiltrated by left-wing ideologies and could soon face a ...

The Benue State Government has reiterated its plans to increase collaboration with key development partners to improve ...

HIV Alliance has received a $12,000 grant from the Cow Creek Umpqua Indian Foundation to support individuals experiencing ...

One in 10 clinics in South Africa will start to hand out a twice-a-year anti-HIV jab as early as February. The country’s medicines regulator, Sahpra, says it’s on track to announce its registration ...

The House of Representatives on Wednesday launched an investigation into how $4.6 billion in international aid grants between 2021 and 2025 were used. It argued that the grants had failed to prevent ...